Rofecoxib's COX-2 Selectivity and Gut Protection
Rofecoxib, sold as Vioxx, selectively inhibits COX-2 enzymes, which drive inflammation and pain. Unlike non-selective NSAIDs like ibuprofen that block both COX-1 and COX-2, rofecoxib spares COX-1. This reduces production of prostaglandins that protect the stomach lining, such as PGE2 and PGI2, leading to fewer gastrointestinal ulcers and bleeding compared to traditional NSAIDs.[1][2]
Clinical Evidence on Stomach Safety
Trials showed rofecoxib caused endoscopic ulcers in 4-6% of users over 6 months, versus 15-20% with naproxen. The VIGOR study reported 50% fewer GI events (perforations, ulcers, bleeds) than naproxen, confirming COX-2 selectivity lowers mucosal damage risk.[3][4]
Limits and Real-World Risks
Protection isn't absolute. High doses or long-term use (over 18 months) still raised ulcer risks in some patients, especially those with prior GI issues. Rofecoxib doesn't eliminate bleeding entirely, as other factors like platelet effects play a role.[2][5]
Why COX-2 Inhibitors Differ from Standard NSAIDs
Traditional NSAIDs inhibit COX-1 heavily, thinning the stomach mucus layer and increasing acid damage. COX-2 drugs like rofecoxib preserve this barrier, but their withdrawal (Vioxx in 2004 due to heart risks) shifted focus to balanced inhibitors like celecoxib.[1][6]
[1]: DrugPatentWatch.com - Rofecoxib patents and pharmacology
[2]: FitzGerald GA, Patrono C. N Engl J Med. 2001;345:433-442.
[3]: Bombardier C, et al. N Engl J Med. 2000;343:1520-1528 (VIGOR trial).
[4]: Laine L, et al. Gastroenterology. 2003;124:684-696.
[5]: FDA Vioxx label and withdrawal summary, 2004.
[6]: Grosser T, et al. Goodman & Gilman's Pharmacological Basis of Therapeutics, 13th ed. Ch. 26.